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ABSTRACT 
The study was aimed at investigating the effects of Brachystegia gum (BG)-egg albumin (EA) mixture as binding agent on 
the qualities of metronidazole tablets. BG and EA were mixed at different ratios to generate fifteen binder mixtures (F1-
F15), from which F1-F5, F6-F10 and F11-F15 were used at 2%, 4% and 6% w/w respectively to formulate metronidazole 
granules by wet granulation. The granules after micromeritic characterization were subsequently compressed into tablets. 
Quality control tests conducted on the tablets include: hardness, friability, weight uniformity and dissolution studies. Results 
reveal that granules flow rates ranged from 3.02 g/s (F4) to 4.73 g/s (F1); angle of repose ranged from 29.06° (F12) to 
35.93° (F3); Carr’s index values were between 7.49% (F9) and 25.43% (F12), while Hausner’s ratio ranged from 1.08 (F9) 
to 1.34 (F12). Tablet hardness values were between 3.65±0.47 (F2) and 5.95±0.60 (F11). Tablets friability values were of 
magnitude ranging from 0.84 (F11) t0 21.73 (F1). The result of weight variation test revealed that only four batches (F4, F6, 
F9 and F15) met compendia specifications. Among the metronidazole tablet formulations, those containing binder at 2% 
w/w released the highest amount of drug, giving up to 90% drug release in 6 h. The least amount of metronidazole was 
released by tablets formulated with binders at 6% w/w from which only about 30% of drug was released in 6 h. The BG-EA 
mixture was found useful in imparting slow release profile on metronidazole tablets, which is desirable for some tablet 
formulations. 
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INTRODUCTION 
Pharmaceutical dosage forms may be developed in which the 
rate or site of release of active ingredient has in some way 
been  modified  compared  with  conventional  release 
formulation. 
[1]  Modified  release  dosage  forms  are 
formulations  where  the  rate  and/or  site  of  release  of  the 
active  ingredient  are  different  from  that  of  the  immediate 
release  dosage  form  administered  by  the  same  route.  This 
deliberate  modification  is  achieved  by  special  formulation 
design  and/or  manufacturing  methods. 
[2]  Various  types  of 
modified  release  formulations  have  been  developed  to 
improve the patient compliance and also clinical efficacy of 
the drug. 
[3] 
Modified release dosage forms are usually a single dose. This 
is advantageous because it is cost-effective, improves patient 
compliance, improve efficacy by reducing any variation in 
drug blood levels, and can ultimately use less of the active  
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ingredient. 
[4] Types of modified release dosage forms have 
been reviewed. 
[2, 5-6] 
Brachystegia eurycoma is an economic tree crop that grows 
in the tropical rainforest of  West  Africa. It belongs to the 
caesalpiniaceae family, the spermatophyte phylum and of the 
order of fabaceae. The crop is classified as legume with its 
pod  containing  seeds  that  are  dicotyledonous. 
[7] 
Brachystegia  eurycoma  seed  contains  56%  carbohydrate, 
15% crude fat, 9% protein, 4.5% ash and 2.9% crude fibre. 
[8] 
In some cultures, the seed flour is used as soup thickening 
and  stabilizing  agent  and  as  emulsifying  agent  in  food 
systems. 
[8-9]  The  seed  gum  from  Brachystegia  eurycoma 
compared favourably with commercial gums used in the food 
industry 
[10]  and  can  be  used  as  a  binding  agent  in  tablet 
formulation. 
[11] Egg albumin is available as dry powder and 
it  is  widely  used  in  the  field  of  foods  and  pharmaceutical 
formulation. As a natural polymer, it has recently attracted 
considerable  attention  in  pharmaceutical  field  due  to  its 
safety. Egg albumin has been evaluated as drug carrier and 
its effect on drugs dissolution was studied for different oral 
formulations such as solid dispersion and microcapsules. 
[12] 
Metronidazole  occurs  as  white-to-pale-yellow  crystals  or 
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to light. It has a melting point between 159°C and 163°C. It 
is  sparingly  soluble  in  water,  alcohol  and  chloroform  and 
slightly soluble in ether.  Its solubility at 20°C (g/100 mL) is 
1.0  in  water,  0.5  in  ethanol  and  <  0.05  in  ether  and 
chloroform. It is soluble in  dilute acids. 
[13] Metronidazole 
has  long  been  the  drug  of  choice  for  the  treatment  of 
trichomoniasis  and,  more  recently  in  combination  with 
iodoquinol,  for  the  treatment  of  symptomatic  amoebiasis, 
except  in  the  brain.  It  is  also  the  drug  of  choice  for  the 
treatment of vaginitis caused by Gardnerella vaginalis. It is 
the alternative drug treatment for giardiasis and guinea worm 
infection. The drug is currently of interest for the treatment 
and  prophylaxis  from  infections  caused  by  anaerobic 
bacteria. Metronidazole has also been reported to be of value 
in Crohn’s disease. 
[13] 
 
MATERIALS AND METHODS 
Materials 
Metronidazole  powder  (Milpharm  and  Almus 
Pharmaceuticals,  UK),  lactose,  egg  albumin,  acetone, 
methanol  (BDH  Chemicals,  UK),  Brachystegia  eurycoma 
seed  (was  purchased  from  a  local  market  in  Elele,  Rivers 
State,  Nigeria),  maize  starch  (M&B  Lagos,  Nigeria), 
chloroform (Fisher Scientific, UK), all other reagents are of 
analytical grade. 
Methods 
Extraction of Brachystegia eurycoma seed gum 
Brachystegia  eurycoma  seeds  were  sun-dried  and  then 
powdered.  The  extraction  was  carried  out  according  to  a 
known method with some modification. 
[5] Two hundred and 
fifty grams (250 g) of the powdered seeds of Brachystegia 
eurycoma was dispersed in 3000 ml of distilled water for 24 
h.  The  mixture  was  centrifuged  and  the  sediment  was 
discarded while the supernatant was kept. Acetone was added 
to the supernatant in the ratio of 1:1 to precipitate the gum. 
This  was  then  centrifuged  at  3000  g  for  30  min,  the 
supernatant was discarded and the sediment kept as gum. The 
gum was further washed with Acetone and then dried at 40
oC 
in an oven for about 48 h. The dry flakes were pulverized 
using a blender and stored in an air tight container. 
 
Table 1: Mixing ratios of binders 
Mixture Code  Brachystegia gum  Egg albumin 
F1  1  1 
F2  1  3 
F3  3  1 
F4  2  0 
F5  0  2 
F6  2  2 
F7  1  3 
F8  3  1 
F9  4  0 
F10  0  4 
F11  3  3 
F12  2  4 
F13  4  2 
F14  6  0 
F15  0  6 
 
Table 2: Formula for Metronidazole tablet 
Ingredient  Quantity 
Metronidazole  333 mg per tablet 
Binder  2.0, 4.0, 6.0% w/w 
Maize starch  5.0% w/w 
Lactose  qs    500 mg 
Magnesium stearate*  1% w/w 
*Quantity is with respect to final granule weight 
 
Preparation of BG-EA mixtures 
The  mixtures  which  were  to  be  used  as  binders  in  wet 
granulation were prepared in accordance to the ratio shown 
in Table 1. 
Formulation of metronidazole granules 
The binders were combined in the ratios shown in Table 1 
and with sufficient amount of distilled water the mucilage of 
each mixture was formed. Mixtures F1 to F5 were used at 2% 
w/w concentration to formulate the granules, while mixtures 
F6 to F10 were used at 4% w/w and mixtures F11 to F15 
were  used  at  6%  w/w  concentrations.  The  granules  were 
formulated with the formula shown in Table 2. In each batch, 
100 tablets were formulated by mixing the required amounts 
of  metronidazole,  maize  starch  and  lactose  in  a  planetary 
mixer for 15 min. The powder mix was then quantitatively 
transferred into a mortar, moistened with the binder mucilage 
and kneaded with pestle to form a wet mass. The wet mass 
was sieved through an aperture of 1000µm, dried at 60°C in a 
hot air oven for 60 min. The granules were screened through 
sieve of aperture size 600 µm and further dried at 60°C for 
60 min and then packed in air tight containers. 
Study of granules flow properties 
Flow rate  
A stainless steel funnel of orifice diameter 1.0 cm was fixed 
using a clamp at a height of 10 cm over a sheet of graph 
paper on a flat horizontal surface, the orifice of the funnel 
was blocked with a stainless steel ruler, and then 15.0 g of 
each composite sample was loaded into the funnel. The ruler 
blocking the orifice was then removed at zero time and the 
time  taken  for  the  powder  to  completely  flow  out  of  the 
funnel  was  noted  using  a  stop  clock.  The  flow  rate  was 
evaluated  using  equation  1.  Triplicate  determinations  were 
made and the mean reported. 
 
Determination of bulk and tapped densities 
The bulk density of each powder sample was determined by 
pouring 20 g (M) of the powder into a 50 ml glass measuring 
cylinder  and  the  bulk  volume  (Vo)  determined.  The  bulk 
density (Db) was then calculated from the relationship: 
 
Triplicate  determinations  were  made  and  the  mean  values 
reported. 
[14]  
The  tapped  density  of  each  powder  was  determined  using 
Stampf  Volumeter  (model  STAV  2003,  JEF  Germany). 
Twenty  grams  (M)  of  each  powder  sample  was  poured 
through 45° angle into a 50 ml glass measuring cylinder and 
the  heap  of  the  powder  levelled  off  horizontally  with  a 
spatula and the bulk volume Vo was read. The cylinder was 
then subjected to 500 taps mechanically and the volume, V500 
of the powder column determined. Tapping was continued to 
750  times  and  the  new  volume,  V750  determined.  The 
difference between V750 and V500 was calculated and if found 
to be < 2%, V750 was used to calculate tapped density (Dt) 
using the relationship: 
 
Triplicate  determinations  were  made  and  the  mean  values 
reported. 
[14] 
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Hausner’s Ratio (HR) and Carr’s Index (CI) were evaluated 
using equations 7 and 8 respectively. 
 
 
Where Dt = tapped density; Db = bulk density. 
The static angle of repose, θ, was measured according to the 
BP (2005) fixed funnel and free standing cone method. 
[15] A 
glass funnel was clamped with its tip of internal diameter, 1 
cm at a given height (h = 2 cm) above a graph paper placed 
on  a  flat  surface.  Twenty  gram  of  powder  sample  was 
carefully poured through the funnel until the apex of the cone 
thus formed just reached the tip of the funnel. The diameter 
(d) of the base of the cone was measured. This procedure was 
repeated three times for each powder/granules and the means 
were used to calculate the angle of repose for each powder 
using equation 6:  
 
Where θ = angle of repose; h = height of powder heap; d = 
diameter of heap base. 
 
Tablet formulation 
The tablet machine (JC – RT - 24H, Jenn Chiang Machinery 
Co.,  LTD,  Feng  –  Yuan,  Taiwan)  was  set  volumetrically 
using relevant granules to compress 500 mg granules and run 
to compress with a force of 15 KN. The granules were then 
lubricated  with  magnesium  stearate  at  0.5  %  w/w  and 
compressed.  The  resulting  tablets  were  stored  in  air  tight 
containers  over  silica  gel  for  72  h  before  relevant  quality 
control tests were conducted on them.  
Quality control tests conducted on the tablets 
Tablet weight uniformity 
Twenty  tablets  selected  at  random  from  each  batch  were 
individually  weighed  using  the  electronic  balance  (Mettler 
Toledo B154, Switzerland) to an accuracy of within ±1 mg. 
The mean weight and percentage deviation from the mean for 
each tablet were calculated. 
Tablet hardness 
The hardness values of ten tablets selected at random from 
each batch were determined at room temperature (32°C) by 
diametral  compression  using  Eweka  hardness  tester  (Karl 
Kolb, Erweka Germany). Results were taken from tablets that 
split cleanly into two halves without any sign of lamination. 
The hardness values were then converted to crushing strength 
by multiplying them by 10 m/s
2 which is acceleration due to 
gravity.  
Friability of tablets 
Ten  tablets  were  de-dusted,  weighed  and  placed  in  the 
friabilator  (Copley/Erweka  GmbH  Type:  TAR  20 
Heusenstamm Germany). The apparatus was operated at 25 
revolutions per  minute (25 rpm) for 4  min. Thereafter the 
tablets were de-dusted and reweighed. The friability of the 
tablets was evaluated with equation 7:  
 
Where Wi = initial weight of the tablets before test;  Wf  = 
final weight of the tablets after test. 
 
Tablets dissolution tests 
Tablets dissolution tests were  carried out according to USP 
XXIII basket method with  an eight chambered dissolution 
test machine (Erweka Germany Type: DT 80) operated at 50 
rpm for 360 min in 900 ml of 0.1 N HCl maintained at 37 ± 
0.5°C  .  Five  milliliter  (5  ml)  of  dissolution  fluid  was 
withdrawn and replaced with 5 ml of fresh medium at the 
following intervals: 10, 20, 30, 40, 50, 60, 120, 180, 240, 300 
and 360  min. Each  withdrawn  sample  was  filtered and  its 
absorbance  determined  with  the  UV-Visible 
spectrophotometer  at  277  nm  using  0.1  N  HCl  as  blank. 
Duplicate  determinations  were  conducted  and  the  mean 
values used to evaluate the percentage drug released using 
the Beer’s plot equation for metronidazole: y = 0.0361x  – 
0.0108,  r
2  =  0.9942,  and  applying  the  appropriate  dilution 
factor. 
 
Table 3: Flow properties of granules 
Binder 
code 
Concentration 
(%w/w) 
Flow 
rate 
(g/s) 
Angle of 
repose 
(
o) 
Carr’s 
index 
(%) 
Hausner’s 
ratio 
F1  2.0  4.73  32.62  11.66  1.13 
F2  2.0  4.59  31.87  11.40  1.15 
F3  2.0  3.15  35.54  13.65  1.17 
F4  2.0  3.02  35.93  18.22  1.22 
F5  2.0  4.54  34.78  22.21  1.29 
F6  4.0  4.69  32.97  19.85  1.25 
F7  4.0  4.54  34.78  17.37  1.21 
F8  4.0  3.40  31.87  23.08  1.28 
F9  4.0  3.20  35.22  7.49  1.08 
F10  4.0  4.35  32.94  8.99  1.10 
F11  6.0  3.91  32.57  20.81  1.26 
F12  6.0  3.39  29.06  25.43  1.34 
F13  6.0  3.50  30.26  22.78  1.30 
F14  6.0  3.42  34.83  22.27  1.29 
F15  6.0  4.55  32.93  17.08  1.21 
 
Table 4: Some mechanical properties of tablets 
Binder Code  No of tablets with 
% error > 5%  Hardness (Kg)  Friability 
(%) 
F1  10  5.10±0.30  21.73 
F2  7  3.65±0.47  2.28 
F3  6  4.65±0.34  8.50 
F4  0  3.80±0.42  10.03 
F5  10  4.15±0.58  12.81 
F6  2  4.20±0.35  6.44 
F7  9  4.65±0.78  8.29 
F8  4  4.05±0.44  5.77 
F9  2  4.75±0.63  4.11 
F10  7  5.90±0.57  5.70 
F11  6  5.95±0.60  0.84 
F12  5  5.85±0.47  1.99 
F13  3  5.05±1.23  1.29 
F14  5  4.25±0.82  0.87 
F15  1  4.55±0.28  3.02 
 
RESULTS  
The flow properties of the granules are shown in Table 3. 
Granules flow rates ranged from 3.02 g/s (F4) to 4.73 g/s 
(F1);  angle  of  repose  ranged  from  29.06°  (F12)  to  35.93° 
(F3);  Carr’s  index  values  were  between  7.49%  (F9)  and 
25.43% (F12), while Hausner’s ratio ranged from 1.08 (F9) 
to 1.34 (F12).  Some mechanical properties of the tablets are 
shown in Table 4, with tablet hardness values lying between 
3.65±0.47 (F2) and 5.95±0.60 (F11). Tablets friability values 
were of magnitude ranging from 0.84 (F11) t0 21.73 (F1). 
The  result  of  weight  variation  test  revealed  that  only  four 
batches (F4, F6, F9 and F15) met compendia specifications. 
The dissolution profile of the various tablet formulations are 
depicted  in  Figures  1-4.  Among  the  metronidazole  tablet 
formulations, those containing binder at 2% w/w released the  Uzondu et al. / Application of Brachystegia eurycoma Gum-Egg Albumen Mixture in the Formulation…..…… 
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highest amount of drug, with albumin alone giving up to 90% 
drug  release  in  6  h.  (Fig.  1).  The  least  amount  of 
metronidazole  was  released  by  tablets  formulated  with 
binders  at  6%  w/w  (Fig.  3).  And  among  these  ones, 
formulating with Brachystegia eurycoma gum alone resulted 
in the release of the smallest amount of drug (Figures 3 & 4).    
DISCUSSION 
The  flowability  of  a  powder  is  an  important  property 
influencing several drug manufacturing steps. Flowability is 
affected by the physical properties of the powder, such  as 
particle size and shape, the loading experienced by particles 
(gravity,  interaction  with  air  flow  and  container  etc.),  the Uzondu et al. / Application of Brachystegia eurycoma Gum-Egg Albumen Mixture in the Formulation…..…… 
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current state of the powder (i.e. tap, free flowing etc.) and the 
processing environment (e.g. humidity). Particles larger than 
250μm usually flow freely while particles below 100µm are 
generally cohesive and prone to flowability problems. 
[16] The 
flow  indices  of  the  granules  (Table  3)  indicate  that  they 
possess  passable  flow  properties. 
[17]  These  types  of  flow 
properties may be improved by the addition of glidants to the 
granules prior to compaction or filling into capsule shells. 
Tablet hardness values were within official recommendations 
[18], except for tablets formulated with F2 or F4 binder whose 
hardness  values  were  less  than  4Kg  (Table  4).  Tablet 
hardness  influences  other  mechanical  properties  of  tablets 
like friability and disintegration. Table 4 however shows that 
in  the  present  study,  tablet  hardness  did  not  have  any 
predictable  influence  on  friability.  This  observation  is  not 
immediately explainable but may be tied to the interaction 
between the two binders whose admixture was employed in 
the formulation. Only two batches, F11 and F14 passed the 
test for friability. 
[19] Four batches, F4, F6, F9 and F15 passed 
the weight uniformity test (Table 4). 
[20] The inability of the 
others  to  meet  the  specification  may  be  due  to  poor  flow 
properties of their granules. Again, one of the main reasons 
for weight variation is inconsistent working height of lower 
punches, or alternatively may be traced to fluctuations in the 
compression pressure of the tableting machine since this has 
been shown to influence tablet weight variation. 
[21-22]  
The results of dissolution studies reveal that all the batches 
exhibited slow release of the drug over 6 h (Figures 1-4). 
Although F5 released as much as 90% of drug (Fig. 1), it did 
not meet the requirement for classification as conventional 
tablet  (should  release  ≥  70%  of  drug  in  60  min). 
[23]  It  is 
therefore  obvious  that  both  Brachystegia  gum  and  egg 
albumin individually imparted slow release on the formulated 
tablets even at low concentration of 2% w/w. The slowest 
release  was  observed  in  tablets  formulated  with  F11at  6% 
w/w.  Tablets  formulated  with  Brachystegia  gum  or  egg 
albumin alone at 6% w/w concentration released more drug 
than F11. This suggests that there may be interaction between 
the  two  excipients  to  form  a  more  occluding  complex 
polymer mix even when mixed simply as was the case in this 
study. Comparison of dissolution of tablets formulated with 
Brachystegia  gum-egg  albumin  reveals  that  F1  stands  out 
(Fig. 4) as the best mixture composition for the formulation 
of slow release metronidazole, since it was able to release 
approximately  90%  of  drug  within  6  h.  Except  where 
targeted release to the colon is the case, delayed release of 
metronidazole  beyond  6  h  may  not  be  particularly 
advantageous  in  ailments  that  are  normally  treated  with 
metronidazole.  However,  multi-  dose  unit  system  of 
metronidazole  may  be  formulated  using  conventional 
metronidazole granules mixed with slow release granules and 
filled in capsules for extended release coverage and for better 
therapeutic outcome. 
 
Brachystegia  gum-egg  albumin  mixture  when  used  as  a 
binding  agent  successfully  slowed  down  the  release  of 
metronidazole from tablets. The mixture is a better retardant 
of drug release than either excipient used alone.  Employing 
the F1 (1:1,  Brachystegia gum : egg albumin) at 2%  w/w 
concentration was found to be good for the slow release of 
metronidazole from tablets in contrast to other mixture ratios 
which slowed the drug’s release beyond acceptable limits for 
common metronidazole indications.  
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